The effect of 1‐hydroxyvitamin D3 for prolongation of leukemic transformation‐free survival in myelodysplastic syndromes
- 1 September 1991
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 38 (1) , 67-68
- https://doi.org/10.1002/ajh.2830380112
Abstract
Leukemic transformation (LT) free survival was studied in 30 patients with myelodysplastic syndromes (MDS). In 15 cases, 4–6 μg/day of 1-hydroxyvitamin D3 was administered, for a median duration of 17 months (D-group), other subjects had no therapy (N group). LT free survival of the D group had significant advantage over that of the N group according to the Kaplan—Meier method (P < 0.001). In addition, 7 cases in the N group developed acute leukemia, in contrast to only one in the D group (P < 0.05). These results suggest that oral administration of 1-hydroxyvitamin D3 prevents the progression of MDS to overt leukemia under the effect of differentiation capacity from blasts to monocytes.Keywords
This publication has 9 references indexed in Scilit:
- 13-cis-retinoic acid v placebo in myelodysplasia [letter]Blood, 1988
- Randomized study of 13-cis retinoic acid v placebo in the myelodysplastic disordersBlood, 1988
- EFFECT OF 13-cis-RETINOIC ACID ON SURVIVAL OF PATIENTS WITH MYELODYSPLASTIC SYNDROMEThe Lancet, 1987
- Treatment of patients with myelodysplastic syndromes: A reviewScandinavian Journal of Haematology, 1986
- Low dose cytosine arabinoside (Ara C) in myelodysplastic syndromesBritish Journal of Haematology, 1984
- 1α,25-Dihyroxyvitamin D3 induces differentiation of human promyelocytic leukemia cells (HL-60) into monocyte-macrophages, but not into granulocytesBiochemical and Biophysical Research Communications, 1983
- Low dose arabinosyl cytosine for treatment of myelodysplastic syndromes and subacute myeloid leukemiaLeukemia Research, 1983
- Proposals for the classification of the myelodysplastic syndromesBritish Journal of Haematology, 1982
- Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3.Proceedings of the National Academy of Sciences, 1981